287 related articles for article (PubMed ID: 33746945)
1. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
Wu J; Shen J; Han Y; Qiao Q; Dai W; He B; Pang R; Zhao J; Luo T; Guo Y; Yang Y; Wu Q; Jiang W; Zhang J; Zhang M; Li N; Li W; Xia X
Front Immunol; 2021; 12():598799. PubMed ID: 33746945
[TBL] [Abstract][Full Text] [Related]
2. The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman.
Khamis F; Memish Z; Al Bahrani M; Al Nummani H; Al Raisi D; Al Dowaiki S; Chhetri S; Al Fahdi F; Al Yahyai M; Pandak N; Al Bolushi Z; Alarimi Z; Al Hashmi S; Al Salmi I; Al-Zakwani I
J Epidemiol Glob Health; 2021 Jun; 11(2):216-223. PubMed ID: 33605108
[TBL] [Abstract][Full Text] [Related]
3. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
[TBL] [Abstract][Full Text] [Related]
4. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
6. Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients.
Roshandel E; Sankanian G; Salimi M; Jalili A; Salari S; Sadeghi A; Hashemian SM; Moshari MR; Pirsalehi A; Hajifathali A
Transfus Apher Sci; 2021 Aug; 60(4):103141. PubMed ID: 33896671
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
[No Abstract] [Full Text] [Related]
8. COVID-19 convalescent plasma composition and immunological effects in severe patients.
Acosta-Ampudia Y; Monsalve DM; Rojas M; Rodríguez Y; Gallo JE; Salazar-Uribe JC; Santander MJ; Cala MP; Zapata W; Zapata MI; Manrique R; Pardo-Oviedo JM; Camacho B; Ramírez-Santana C; Anaya JM;
J Autoimmun; 2021 Mar; 118():102598. PubMed ID: 33524876
[TBL] [Abstract][Full Text] [Related]
9. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
11. Immune reactivity during COVID-19: Implications for treatment.
Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
[TBL] [Abstract][Full Text] [Related]
12. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
[TBL] [Abstract][Full Text] [Related]
14. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
17. Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2.
Chen JT; Ostermann M
Crit Care Clin; 2022 Jul; 38(3):587-600. PubMed ID: 35667745
[TBL] [Abstract][Full Text] [Related]
18. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
Calderón-Ochoa C; Plamenov-Donchev N; Hernández-Quiñones F; Mendoza-López O; Hinojos-Gallardo LC; Longino-Gómez AJ; Hernádez-Saldaña R; Duque-Rodríguez J; Ishida-Gutiérrez MC
Microbiol Spectr; 2024 Jun; 12(6):e0249823. PubMed ID: 38687065
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
